On July 8, 2022 Herantis Pharma Plc reported that has appointed Antti Vuolanto (born 1975) as CEO as of 22July2022 (Press release, Herantis Pharma, JUL 8, 2022, View Source,c3598918 [SID1234616555]). Frans Wuite will continue as interim CEO of Herantis Pharma Plc until 21July2022 and as Member of the Board also thereafter.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Antti Vuolanto has acted as the Chief Operating Officer of Herantis Pharma Plc since 2018. Vuolanto graduated as Doctor of Science in Technology at Aalto University, Finland in 2004 in biochemistry and bioprocess technology. He has vast experience in biological drug development, gene therapy products, in-vitro diagnostics, and bioinformatics.

"The Board of Directors commenced the CEO recruitment process in January this year. I am very pleased that, after careful evaluation, we found an internal successor within the company who is well equipped to take over the role of CEO. As a result of his management position in the company, Antti Vuolanto has strong experience and knowledge of Herantis’ business and strategic development, as well as due to his background, expertise in the company’s field of business, research, and product development. Antti has also demonstrated his commitment to the company and its development over the past few years. We thank Frans Wuite for his contribution as interim CEO of Herantis and wish Antti all the best in his new future role," says Timo Veromaa, Chairman of the Board of Herantis.

"It has been an honour to be closely involved in the development of Herantis and the company’s strategy over the last few years and to participate in the important work Herantis is doing in developing disease modifying therapies for Parkinson’s Disease. In my new role, I am able to utilize my knowledge of Herantis’ industry, business and strategic development, and I am excited about the opportunity to participate in Herantis’ next phases in a new role as CEO. I thank the Board of Directors of Herantis for the trust it has shown," says Antti Vuolanto.